Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and...
12 Best Rising Penny Stocks To Buy
Investors in Heron Therapeutics (NASDAQ:HRTX) From Five Years Ago Are Still Down 90%, Even After 23% Gain This Past Week
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Profit Outlook
We feel now is a pretty good time to analyse Heron Therapeutics, Inc.'s (NASDAQ:HRTX) business as it appears the company may be on the cusp of a considerable accomplishment. Heron Therapeutics, Inc.
Heron Therapeutics Gains FDA Nod for ZYNRELEF Expansion
Heron Therapeutics' Non-Opioid, Post-Operative Pain Drug Approved For Use In Additional Orthopedic, Soft Tissue Procedures - FDA Gives Nod
The FDA has approved Heron Therapeutics Inc's (NASDAQ:HRTX) supplemental New Drug Application for Zynrelef (bupivacaine and meloxicam) extended-release solution to expand the indication for soft tissu